In a move expected to increase competition and lower drug prices, the Food and Drug Administration today approved the first “biosimilar” drug, designed to closely mimic existing drugs grown in living cells.¬†Pharmaceutical companies have been able to produce low-cost generic drugs for three decades, but they haven’t before been able to produce knockoff versions of these more complicated therapies.

Click Here to read more